Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome.
Biologics
Hereditary non-polyposis colorectal cancer
Immunosuppression
Inflammatory bowel disease
Lynch syndrome
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 Jan 2022
24 Jan 2022
Historique:
received:
09
04
2021
revised:
11
08
2021
accepted:
22
12
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
5
2
2022
Statut:
ppublish
Résumé
Individuals with Lynch syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC) are at increased risk of both colorectal cancer and other cancers. The interplay between immunosuppression, a comorbid inflammatory condition (CID), and HNPCC on cancer risk is unclear. To evaluate the impact of CIDs, and exposure to monoclonal antibodies and immunomodulators, on cancer risk in individuals with HNPCC. Individuals prospectively followed in a hereditary cancer registry with LS/HNPCC with the diagnosis of inflammatory bowel disease or rheumatic disease were identified. We compared the proportion of patients with cancer in LS/HNPCC group with and without a CID. We also compared the proportion of patients who developed cancer following a CID diagnosis based upon exposure to immunosuppressive medications. A total of 21 patients with LS/HNPCC and a CID were compared to 43 patients with LS/HNPCC but no CID. Cancer occurred in 84.2% with a CID compared to 76.7% without a CID ( In patients with LS/HNPCC, the presence of a concurrent inflammatory condition, or use of immunosuppressive medication to treat the inflammatory condition, might not increase the rate of cancer occurrence in this limited study.
Sections du résumé
BACKGROUND
BACKGROUND
Individuals with Lynch syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC) are at increased risk of both colorectal cancer and other cancers. The interplay between immunosuppression, a comorbid inflammatory condition (CID), and HNPCC on cancer risk is unclear.
AIM
OBJECTIVE
To evaluate the impact of CIDs, and exposure to monoclonal antibodies and immunomodulators, on cancer risk in individuals with HNPCC.
METHODS
METHODS
Individuals prospectively followed in a hereditary cancer registry with LS/HNPCC with the diagnosis of inflammatory bowel disease or rheumatic disease were identified. We compared the proportion of patients with cancer in LS/HNPCC group with and without a CID. We also compared the proportion of patients who developed cancer following a CID diagnosis based upon exposure to immunosuppressive medications.
RESULTS
RESULTS
A total of 21 patients with LS/HNPCC and a CID were compared to 43 patients with LS/HNPCC but no CID. Cancer occurred in 84.2% with a CID compared to 76.7% without a CID (
CONCLUSION
CONCLUSIONS
In patients with LS/HNPCC, the presence of a concurrent inflammatory condition, or use of immunosuppressive medication to treat the inflammatory condition, might not increase the rate of cancer occurrence in this limited study.
Identifiants
pubmed: 35116232
doi: 10.5306/wjco.v13.i1.49
pmc: PMC8790302
doi:
Types de publication
Journal Article
Langues
eng
Pagination
49-61Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Authors have no conflicts of interest to disclose.
Références
Gastroenterology. 2004 Feb;126(2):451-9
pubmed: 14762782
Gastroenterology. 2013 Jul;145(1):166-175.e8
pubmed: 23541909
Immunity. 2003 Jan;18(1):1-6
pubmed: 12530970
Arthritis Rheum. 2010 Aug;62(8):2517-24
pubmed: 20506368
Urol Oncol. 2013 Jul;31(5):716
pubmed: 23796201
Rheumatology (Oxford). 2011 Aug;50(8):1431-9
pubmed: 21415022
JAMA. 2006 May 17;295(19):2275-85
pubmed: 16705109
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Gastroenterology. 2017 Sep;153(3):827-834
pubmed: 28780013
Ann Rheum Dis. 2011 Nov;70(11):1895-904
pubmed: 21885875
Anticancer Agents Med Chem. 2016;16(1):101-7
pubmed: 26299661
J Gastroenterol. 2010;45(1):9-16
pubmed: 19960355
Clin Gastroenterol Hepatol. 2017 Mar;15(3):454-458.e1
pubmed: 27521512
Oncology. 2006;71(1-2):124-30
pubmed: 17347588
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Am J Gastroenterol. 2017 Feb;112(2):241-258
pubmed: 28071656
Aliment Pharmacol Ther. 2018 Feb;47(3):318-331
pubmed: 29205426
JAMA. 2012 Oct 17;308(15):1555-65
pubmed: 23073952
Arthritis Rheum. 2004 Jun;50(6):1740-51
pubmed: 15188349
J Crohns Colitis. 2014 Oct;8(10):1281-6
pubmed: 24662394
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
Clin Gastroenterol Hepatol. 2020 Feb;18(2):294-296
pubmed: 31408703
Trends Cancer. 2016 Mar;2(3):121-133
pubmed: 28741532
Eur J Cancer. 1996 Sep;32A(10):1753-7
pubmed: 8983286
Int J Colorectal Dis. 2016 Jan;31(1):9-13
pubmed: 26412249
Cancer Res. 2002 Apr 1;62(7):2092-7
pubmed: 11929830
Arthritis Res Ther. 2008;10(2):R45
pubmed: 18433475
Gut. 2008 Aug;57(8):1097-101
pubmed: 18364438
Cancer Res. 1995 Dec 15;55(24):6092-6
pubmed: 8521398
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
J Exp Med. 2002 Jan 21;195(2):161-9
pubmed: 11805143
N Engl J Med. 1990 Dec 20;323(25):1767-9
pubmed: 2247108
Arthritis Rheum. 2007 Sep;56(9):2886-95
pubmed: 17729297
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328